Interferon-alpha-induced psychiatric side effects in patients with chronic viral hepatitis: a prospective, observational, controlled study

2005 ◽  
Vol 14 (3) ◽  
pp. 145-153 ◽  
Author(s):  
M. Germana Orrù ◽  
Antonella Baita ◽  
Rossella Sitzia ◽  
Alessandra Costa ◽  
Elisabetta Muntoni ◽  
...  
Keyword(s):  
Side Effects ◽  
Adverse Effects ◽  
Viral Hepatitis ◽  
Interferon Alpha ◽  
Psychiatric Diagnosis ◽  
Chronic Viral Hepatitis ◽  
Ifn Alpha ◽  
Psychiatric Side Effects ◽  
Psychiatric Adverse Effects ◽  
Alpha Therapy

SUMMARYAims— Patients with chronic viral hepatitis suffer from a high prevalence of psychiatric problems. Furthermore, the treatment for chronic viral hepatitis, with interferon (IFN) alpha, induces the occurrence of further psychopathological symptoms. The autors examined whether patients with a pre-existing psychiatric diagnosis had more severe IFN alpha-induced psychiatric adverse effects, and whether they were more likely to interrupt the IFN alpha therapy, compared with control patients with no pre-existing psychiatric diagnosis. They also examined the psychopharmacological management of the interferon-alpha-induced psychiatric side effects.Methods— The authors studied prospectively 60 patients with chronic hepatitis B or C in Cagliari, Italy. Patients underwent psychiatric assessment before starting interferon alpha and monthly throughout the therapy.Results— After adjusting for the baseline psychopathology, there was no statistically significant difference in interferon-alpha-induced psychiatric adverse effects between patients with a pre-existing psychiatric diagnosis and controls. There was also no evidence that psychiatric cases were more likely than controls to interrupt the IFN alpha therapy because of psychiatric side effects. Moreover, there was no difference in the psychiatric adverse effects severe enough to require psychopharmacological treatment. Finally, psychopharmaco-logical management successfully treated psychiatric symptoms induced by the IFN alpha.Conclusions— Patients with a pre-existing psychiatric diagnosis do not have a specific vulnerability to interferon-alpha-induced psychiatric adverse effects.Declaration of Interest: none of the authors have conflict of interests in writing this paper; CM. Pariante is funded by the UK Medical Research Council and by the NARSAD and the Guy's and St Thomas Charity

scholarly journals Autoantibodies before, during and after administration of recombinant interferon-alpha for chronic viral hepatitis

1995 ◽  
Vol 37 (5) ◽  
pp. 455-460 ◽  
Author(s):  
Edmundo P.A. Lopes ◽  
A. Eduardo Silva ◽  
Hoel Sette Junior ◽  
Rubens X. Guimarães ◽  
M. Lucia Ferraz
Keyword(s):  
Viral Hepatitis ◽  
Interferon Alpha ◽  
Poor Response ◽  
Chronic Viral Hepatitis ◽  
Control Group ◽  
Type B ◽  
Recombinant Interferon ◽  
Ifn Alpha ◽  
Ifn Therapy ◽  
Type C

This study was undertaken to investigate the presence of autoantibodies in patients with chronic viral hepatitis B and C, before, during and after interferon-alpha (IFN-alpha) therapy and to study their relation to dose and type of IFN-alpha and response to treatment. Fifty patients with chronic hepatitis were divided in two groups, a control-group of 21 patients (10 type B and 11 type C) who were followed for 6 months without treatment and an IFN-group consisting of 29 patients (8 type B and 21 type C) who received IFN therapy for 6 months. Serum samples were tested for a range of antibodies at the start of the study, during therapy and at the end of the 6 month period. Antibodies tested for included: antinuclear, smooth muscle, antimitochondrial, parietal cell and thyroid microsomal. Four (8%) of the total patient group had autoantibodies at the beginning of the study (two in each group). During the follow-up period no patient in the control group developed antibodies compared with 3 (11%) patients in the treatment group. Autoantibodies developed in patients treated with higher doses of IFN and were found in those patients who tended to show a poor response to IFN-therapy. Further studies are needed to establish the relationship between poor response to IFN-alpha and development of autoantibodies.

scholarly journals Effective natural interferon-alpha therapy in recombinant interferon- alpha-resistant patients with hairy cell leukemia

Blood ◽  
1991 ◽  
Vol 78 (1) ◽  
pp. 38-43 ◽  
Author(s):  
P von Wussow ◽  
H Pralle ◽  
HK Hochkeppel ◽  
D Jakschies ◽  
S Sonnen ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Hairy Cell Leukemia ◽  
Mononuclear Cells ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Recombinant Interferon ◽  
Homologous Protein ◽  
Ifn Alpha ◽  
Interferon Alpha Therapy ◽  
Alpha Therapy

Abstract To explore the relationship between anti-interferon-alpha (anti-IFN- alpha) antibodies and loss of clinical responsiveness to IFN-alpha treatment, we examined sera from 59 patients with hairy cell leukemia who responded to therapy with recombinant IFN-alpha-2a (rIFN-alpha-2a). During the first 2 years of therapy, 10 patients developed rIFN-alpha- 2a-neutralizing and 15 rIFN-alpha-2a-binding antibodies. Nine of the 59 initially responding patients became resistant to rIFN-alpha-2a and suffered a relapse of the disease at 7 to 24 months of treatment. All nine relapsing patients tested positive for both neutralizing and binding antibodies with titers above 400 INU/mL, while none of the antibody-negative patients relapsed. Six patients with detectable binding antibody titers below 400 INU/mL continued to respond to treatment. By measuring the IFN kinetics and the levels of the IFN- induced Mx-homologous protein in mononuclear cells after a single injection each of rIFN-alpha-2a and nIFN-alpha the IFN antibodies of eight of the nine resistant rIFN-alpha patients were found to be highly specific for rIFN-alpha-2a. Therefore, these eight patients were switched to natural IFN-alpha (nIFN-alpha) therapy at doses of 3 million IU, three times a week. All eight patients responded to treatment with nIFN-alpha, achieving durable objective responses similar to those obtained previously with rIFN-alpha-2a. These data clearly demonstrate that rIFN-alpha antibody-positive patients can effectively be treated with nIFN-alpha.

scholarly journals c-myc and c-fos expression during interferon-alpha therapy for hairy cell leukemia

Blood ◽  
1986 ◽  
Vol 68 (4) ◽  
pp. 967-970 ◽  
Author(s):  
P Lehn ◽  
F Sigaux ◽  
D Grausz ◽  
P Loiseau ◽  
S Castaigne ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Hairy Cell Leukemia ◽  
Low Dose ◽  
Mrna Levels ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Prolymphocytic Leukemia ◽  
Ifn Alpha ◽  
Alpha Therapy

Abstract Low-dose interferon-alpha (IFN-alpha) therapy is consistently effective in the treatment of hairy cell leukemia (HCL). In two cases of resistance to IFN-alpha administration, we diagnosed variant HCL, a form of HCL with intermediate features between typical HCL and B cell prolymphocytic leukemia. We tried to distinguish variant and typical hairy cells (HCs) by Northern blot analysis of the oncogenes expressed in vivo. We report that variant HCs contain c-myc transcripts in contrast to typical HCs, whereas c-fos transcripts are detected in both cell types. We also report that the mRNA levels of c-myc are not modified in variant HCs by IFN-alpha treatment, whereas the level of c- fos mRNA is modulated in both types of HCs. Our findings suggest that the failure to modulate c-myc expression in vivo might indicate the limits of low-dose IFN-alpha therapy.

scholarly journals The use of Ingaron® in the treatment of chronic viral hepatitis B

2020 ◽  
Vol 20 (5-6) ◽  
pp. 63-67
Author(s):  
Ekaterina A. Zaytseva ◽  
Larisa L. Popova ◽  
Dmitry Yu. Konstantinov
Keyword(s):  
Side Effects ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Antiviral Therapy ◽  
Treatment Regimen ◽  
Chronic Viral Hepatitis ◽  
Immunomodulating Therapy ◽  
Number Of Patients ◽  
Viral Hepatitis B ◽  
Clinically Significant

The possibility of antiviral therapy with the direct antiviral drugs Entecavir and Ingaron, as an antiviral and immunomodulating therapy, was studied in patients with the recurrent chronic viral hepatitis B. The study showed the applicability of this treatment regimen, due to the increase in the number of patients with SVR, high tolerability and the absence of clinically significant side effects.

Sign in / Sign up

Export Citation Format

Share Document